NCT06952452View on ClinicalTrials.gov

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

PHASE3RecruitingINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

Bevacizumab

The dosage for each intravitreal injection is 1.25mg of BVZ in 0.05ml

DRUG

Ranibizumab Ophthalmic

The dosage for each intravitreal injection contains 0.5mg of RBZ in 0.05ml

Trial Locations (3)

Unknown

RECRUITING

Hospital Universitario de Canarias, San Cristóbal de La Laguna

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

RECRUITING

Hospital la Esperanza, Barcelona

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Parc de Salut Mar

OTHER